Alzheimer's blood-brain barrier nanoparticle research | Healthcare Discovery
| | |

Resistance Training Is Medicine for Your Brain: What 2026 Research Reveals About Strength Training, Depression, and Cognitive Decline

A growing body of clinical evidence shows that resistance training reduces depression symptoms as effectively as frontline medications, slows cognitive decline in aging adults, and triggers neurobiological changes that no…

Healthcare Discovery gut microbiome brain heart kidney axis 2026 research showing microbial signals connecting major organs
| | |

Your Gut Microbiome Is Talking to Your Brain, Heart, and Kidneys: Five 2026 Studies Reveal the Body’s Hidden Communication Network

A Stanford Nature study shows gut bacteria drive age-related memory loss through vagus nerve inflammation, while new research in Nature Communications, npj Biofilms and Microbiomes, and Microbiology Spectrum reveals that…

Consistent sleep-wake rhythm aligning brain, heart, and metabolic signals for longevity
| | |

Sleep Regularity May Matter More Than Sleep Duration for How Long You Live: What 60,977 People and Three Landmark Studies Reveal About the Dimension of Sleep Most People Ignore

A landmark UK Biobank study of 60,977 people found that sleep regularity is a stronger predictor of mortality than sleep duration, reducing all-cause death risk by 30 percent. Combined with…

Healthcare Discovery GLP-1 drugs Alzheimer brain EVOKE trial neurodegeneration 2026 showing metabolic signals and brain biomarkers
| | |

GLP-1 Drugs and the Brain: Why the Biggest Alzheimer’s Trial Failed but the Science Is Far From Over

The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from…

David Fajgenbaum of Every Cure, the nonprofit focused on AI-powered drug repurposing
| | |

The Cure Hiding in Plain Sight: How Every Cure Is Rewriting the Rules of Drug Discovery

Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life,…

The Daily Rounds: Longevity & Health Care Brief | April 3, 2026
|

The Daily Rounds: Longevity & Health Care Brief | April 3, 2026

🧬 - Epigenetic reprogramming enters human trials for the first time, with Life Biosciences' ER-100 receiving FDA clearance for a phase 1 study in optic nerve degeneration, marking the dawn of cellular rejuvenation medicine. 🫁 - An AI-designed molecule for idiopathic pulmonary fibrosis shows clinical promise in a phase 2a trial, proving that algorithmically discovered drugs can survive contact with human biology. 🦠 - Gut bacteria can inject proteins directly into human cells, a newly described mechanism now linked to Crohn's disease inflammation and poised to reshape microbiome therapeutics. 🧠 - Disrupted circadian rhythms are associated with 2.5 times the risk of dementia, reinforcing that sleep timing and biological clock integrity are modifiable targets for brain aging. 💊 - With more than 173 AI-discovered drug programs now in clinical trials and Eli Lilly committing $2.75 billion to AI drug development, the algorithmic era of medicine is no longer theoretical.

VO2 max testing and oxygen metabolism illustrating cardiorespiratory fitness as a longevity biomarker | Healthcare Discovery
| | |

Your VO2 Max May Be the Single Best Predictor of How Long You Will Live: What 3.8 Million People and 58 Clinical Trials Reveal About Cardiorespiratory Fitness and the Science of Living Longer

A meta-analysis of 3.8 million people shows that each one-MET increase in cardiorespiratory fitness reduces all-cause mortality by 14 percent. A 2026 Cochrane review of 58 clinical trials confirms HIIT…